Zach Reitano shows cutting healthcare middlemen drops drug prices

By Ruth Behrens · Reporting from Newell, Iowa ·

Podcast

When hogs hit eight cents a pound, my family learned the hard truth about consolidated markets. When four big packers control the scale, the family at the gate gets crushed while the consumer still pays top dollar at the grocery counter. The exact same rot has infected American healthcare. On the podcast Invest Like the Best, Zach Reitano, co-founder and chief executive of the telehealth company Ro, told host Patrick O'Shaughnessy that the primary flaw in our medical system is that the patient is simply not the customer. Whoever controls the cash at the register is the stakeholder built around. For decades, that stakeholder has been a syndicate of corporate insurance companies and Pharmacy Benefit Managers (PBMs).

Reitano reported a striking piece of evidence. When pharmaceutical manufacturers began selling GLP-1 weight-loss treatments directly to consumers for cash, bypassing insurance middlemen entirely, list prices plummeted from $1,300 a month down to $149. The drugmakers actually made equal or better profits on high volume, while working Americans got relief without a bureaucrat standing between them and their doctor.

The Market Breakdown at the Pharmacy Counter

Politicians of every stripe have delivered speeches demanding hospital price transparency, yet list prices on branded medications systematically climb every single year. That is not a free market. It is an opaque cartel. Reitano described PBMs as the "appendix of the healthcare system" — a vestigial organ that once served a purpose but now exists only to collect spreads, demand behind-the-scenes rebates, and artificially inflate list prices so they can claim credit for negotiating discount crumbs.

Consider the numbers Reitano put on the board. Americans currently spend 18 percent of national gross domestic product on medical care. Yet staggering outlays go toward treating chronic illnesses in just five percent of the population. We do not pay for healthcare directly through clear receipts. We pay for it through suppressed wages, inflated property taxes for municipal health coverage, and astronomical monthly premiums. When you do not know what a service costs until ninety days after you receive it, price discovery is impossible. Free enterprise cannot function in the dark.

Cut Out the Corporate Appendices

The defenders of our current third-party payer apparatus will argue that PBMs and legacy insurers provide essential bulk-purchasing leverage, shielding working families from the unmitigated pricing power of giant pharmaceutical corporations. Without institutional negotiation, they claim, low-income patients would be tossed to the whims of the open market.

That argument crumbles against the balance sheet. When Novo Nordisk and Eli Lilly went direct to consumers through digital distribution platforms like Ro, net prices dropped. Volume exploded, unit costs fell, and software handled the administrative verification that used to require armies of paper-pushing middle managers. As Reitano noted, twice as many individual Americans now pay out-of-pocket for GLP-1 medications than pay for consumer AI subscriptions. When people are allowed to vote with their own hard-earned dollars, they demand lower prices and better service, and the market delivers.

A nation that surrenders its health system to administrative middlemen is no more sovereign than a farm town that lets four packers set the price of cattle. If conservative policymakers want to deliver real healthcare relief to working families, they should stop tinkering with bureaucratic insurance mandates and start severing the middlemen from the flow of cash. Force every drug maker and hospital to post their real cash price, let patients carry their own health dollars, and watch the cost of staying alive fall back to earth.

Sources

  1. GLP-1s Are a Bigger Business Than AI